Allogene Therapeutics, Inc. cash flow to debt ratio of -179.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Allogene Therapeutics, Inc.'s free cash flow has increased -25.55% from $-200.99M last year to $-149.63M, signaling increasing performance

Allogene Therapeutics, Inc.'s debt to equity ratio is 0.29, which means that the company's assets are healthy financed, signaling financial stability.

Allogene Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.21 last year to 0.29 today, signaling weakened financials

Allogene Therapeutics, Inc. has a net cash position, so leverage is healthy.

Allogene Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Allogene Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -1.17M% to 0.00%, signaling increasing performance

Allogene Therapeutics, Inc.'s short-term assets of $257.75M exceed its short-term liabilities of $32.51M

Allogene Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Allogene Therapeutics, Inc.'s return on equity of -56.45%, is lower than 15.00%, indicating bad performance

Allogene Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Allogene Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Allogene Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Allogene Therapeutics, Inc. has negative free cash flow, indicating cash burn

Allogene Therapeutics, Inc.'s yearly earnings has increased -25.90% since last year from $-257.59M to $-190.89M, signaling increasing performance

Allogene Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $22.00K to $0.00, signaling decreasing performance

ROIC -50.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Allogene Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Allogene Therapeutics, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Allogene Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Allogene Therapeutics, Inc. has insufficient data to evaluate this check.

Allogene Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Allogene Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Allogene Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Allogene Therapeutics, Inc. has insufficient data to evaluate this check.

Allogene Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Allogene Therapeutics, Inc. has a price-to-book ratio of 1.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Allogene Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue